CN103239421B - 氟伐他汀钠组合物胶囊及其制备方法 - Google Patents
氟伐他汀钠组合物胶囊及其制备方法 Download PDFInfo
- Publication number
- CN103239421B CN103239421B CN201310165570.1A CN201310165570A CN103239421B CN 103239421 B CN103239421 B CN 103239421B CN 201310165570 A CN201310165570 A CN 201310165570A CN 103239421 B CN103239421 B CN 103239421B
- Authority
- CN
- China
- Prior art keywords
- fluvastatin
- fluvastatin sodium
- sodium
- composition capsule
- capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
项目 | 显效 | 有效 | 无效 | 恶化 | 总有效率(%) |
TC | 24 | 13 | 5 | 0 | 88(37/42) |
TG | 12 | 14 | 10 | 6 | 61(36/42) |
LDL—C | 30 | 6 | 3 | 3 | 85(36/42) |
项目 | 显效 | 有效 | 无效 | 恶化 | 总有效率(%) |
TC | 20 | 6 | 4 | 0 | 86(26/30) |
TG | 8 | 12 | 6 | 4 | 66(20/30) |
LDL—C | 21 | 5 | 3 | 1 | 86(26/30) |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310165570.1A CN103239421B (zh) | 2013-05-08 | 2013-05-08 | 氟伐他汀钠组合物胶囊及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310165570.1A CN103239421B (zh) | 2013-05-08 | 2013-05-08 | 氟伐他汀钠组合物胶囊及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103239421A CN103239421A (zh) | 2013-08-14 |
CN103239421B true CN103239421B (zh) | 2015-06-03 |
Family
ID=48919528
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310165570.1A Active CN103239421B (zh) | 2013-05-08 | 2013-05-08 | 氟伐他汀钠组合物胶囊及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103239421B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1825848A2 (de) * | 2006-02-10 | 2007-08-29 | Stada Arzneimittel Ag | Stabile pharmazeutische Zusammensetzungen umfassend einen HMG-CoA-Reduktase Inhibitor |
-
2013
- 2013-05-08 CN CN201310165570.1A patent/CN103239421B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1825848A2 (de) * | 2006-02-10 | 2007-08-29 | Stada Arzneimittel Ag | Stabile pharmazeutische Zusammensetzungen umfassend einen HMG-CoA-Reduktase Inhibitor |
Also Published As
Publication number | Publication date |
---|---|
CN103239421A (zh) | 2013-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Montuschi | Role of leukotrienes and leukotriene modifiers in asthma | |
Xu et al. | Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects | |
CN107365680A (zh) | 一种利用名酒大曲制备的食醋/醋膏及其应用 | |
Alloway et al. | Pharmacokinetics in stable heart transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations | |
Malik et al. | Serum sialic acid changes in non-insulin-dependant diabetes mellitus (NIDDM) patients following bitter melon (Momordica charantia) and rosiglitazone (Avandia) treatment | |
JP7061611B2 (ja) | バチルスアミロリケファシエンスgf423菌株、及びそれによって生産されるポリペプチドを含む抗酸化及び抗炎症活性を提供するかあるいは脂質異常症を予防又は治療する組成物 | |
CN101485463A (zh) | 一种具有多种保健功效的天然产品组方 | |
Yi et al. | Hypouricemic effect of the methanol extract from Prunus mume fruit in mice | |
JP2009518312A (ja) | 疾患を治療するための植物浸出物の組成物および使用 | |
KR20010101790A (ko) | (e)-7-[4-(4-플루오로페닐)-6-이소프로필-2-[메틸(메틸술포닐)아미노]피리미딘-5-일](3r,5s)-3,5-디히드록시헵트-6-엔산 및 p450 이소효소 3a4의 억제제, 유도제 또는기질을 함유하는 약물 조합물 | |
CN109223707A (zh) | 一种尿酸酶外用凝胶制剂、其制备方法及用途 | |
CN102675199B (zh) | 一种蛋白质络氨酸磷酸酶抑制剂、其制备方法及其用途 | |
Tomita et al. | Effect of food thickener and jelly wafer on the pharmacokinetics of levofloxacin orally disintegrating tablets | |
Aquaron | Alkaptonuria in France: past experience and lessons for the future | |
Hu et al. | The hypolipidemic effect of hawthorn leaf flavonoids through modulating lipid metabolism and gut microbiota in hyperlipidemic rats | |
CN109939120A (zh) | 含烟酰胺单核苷酸和罗汉果苷的组合物及其应用 | |
Hosseinzadeh et al. | Brewer’s yeast improves blood pressure in type 2 diabetes mellitus | |
CN103239421B (zh) | 氟伐他汀钠组合物胶囊及其制备方法 | |
Krongvorakul et al. | Pharmacokinetics of mitragynine in man | |
CN109045070A (zh) | 一种防治非酒精性脂肪肝病的组合物 | |
Cicero et al. | Long-term effectiveness and safety of a nutraceutical based approach to reduce cholesterolemia in statin intolerant subjects with and without metabolic syndrome. | |
CN102342949B (zh) | 根皮苷在制备治疗高尿酸血症药物中的应用 | |
CN105319332A (zh) | 一种基于生物效价的降血脂类中药质量评价方法 | |
CN106177227A (zh) | 一种增强人体免疫力的含辅酶q10的组合物 | |
Koehler et al. | Reuse of molecules for glioblastoma therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent for invention or patent application | ||
CB02 | Change of applicant information |
Address after: Seven of 276017 Shandong province Linyi city Luozhuang District Applicant after: Shandong Luo Xin Pharmaceutical Group Plc Address before: Seven of 276017 Shandong province Linyi city Luozhuang District Applicant before: SHANDONG LUOXIN PHARMACY STOCK Co., LTD. |
|
CB03 | Change of inventor or designer information |
Inventor after: Yang Hengzhe Inventor after: Li Mingjie Inventor after: Chen Yu Inventor after: Gao Feifei Inventor after: Liu Yanzhen Inventor after: Shao Yang Inventor before: Li Mingjie Inventor before: Chen Yu Inventor before: Gao Feifei Inventor before: Liu Yanzhen Inventor before: Shao Yang |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LI MINGJIE CHEN YU GAO FEIFEI LIU YANZHEN SHAO YANG TO: YANG HENGZHE LI MINGJIE CHEN YU GAO FEIFEI LIU YANZHEN SHAO YANG Free format text: CORRECT: APPLICANT; FROM: SHANDONG LUOXIN PHARMACY STOCK CO., LTD. TO: SHANDONG LUOXIN PHARMACY GROUP CO., LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |